Journal of Clinical Epidemiology
Volume 55, Issue 4 , Pages 345-349 , April 2002

Cardiovascular risk factors and diseases precede oral hypoglycaemic therapy in patients with type 2 diabetes mellitus

  • Joëlle A. Erkens

      Affiliations

    • Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, Netherlands
    • Julius Center for Patient Oriented Research, University Medical Center Utrecht, Utrecht, Netherlands
    • Corresponding Author InformationCorresponding author. Joëlle A. Erkens, Department of Pharmacoepidemiology & Pharmacotherapy Utrecht Institute for Pharmaceutical Sciences (UIPS), PO Box 80082, 3508 TB Utrecht, The Netherlands. Email: Telephone: +31 (0) 30 2536976/7324. Fax: + (0) 30 2539166
    • ,
  • Ron M.C. Herings

      Affiliations

    • Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, Netherlands
    • ,
  • Ronald P. Stolk

      Affiliations

    • Julius Center for Patient Oriented Research, University Medical Center Utrecht, Utrecht, Netherlands
    • ,
  • José A. Spoelstra

      Affiliations

    • Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, Netherlands
    • Julius Center for Patient Oriented Research, University Medical Center Utrecht, Utrecht, Netherlands
    • ,
  • Diederick E. Grobbee

      Affiliations

    • Julius Center for Patient Oriented Research, University Medical Center Utrecht, Utrecht, Netherlands
    • ,
  • Hubert G.M. Leufkens

      Affiliations

    • Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, Netherlands

Received 29 November 2000 ,Revised 3 August 2001 ,Accepted 30 August 2001.

References 

  1. Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis. 1998;137(Suppl):S65–S73
  2. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607
  3. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 1994;43(8):960–967
  4. Haffner SM, Miettinen H, Stern MP. Relatively more atherogenic coronary heart disease risk factors in prediabetic women than in prediabetic men. Diabetologia. 1997;40(6):711–717
  5. McPhillips JB, Barrett-Connor E, Wingard DL. Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults. Am J Epidemiol. 1990;131(3):443–453
  6. Herings RM, Stricker BH, de Boer A, Bakker A, Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med. 1995;155(16):1801–1807
  7. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45(2):197–203
  8. Psaty BM, Koepsell TD, Lin D, Weiss NS, Siscovick DS, Rosendaal FR, et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc. 1999;47(6):749–754
  9. Selvin S. Statistical Analysis of epidemiological. Second ed. Vol. 25. New York: Oxford University Press; 1996.
  10. Rendell M, Lassek WD, Ross DA, Smith C, Kernek S, Williams J, et al. A pharmaceutical profile of diabetic patients. J Chronic Dis. 1983;36(2):193–202
  11. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA. 1990;263(21):2893–2898[see comments]
  12. Stolk RP, van Splunder IP, Schouten JS, Witteman JC, Hofman A, Grobbee DE. High blood pressure and the incidence of non-insulin dependent diabetes mellitus (findings in a 11.5 year follow-up study in The Netherlands). Eur J Epidemiol. 1993;9(2):134–139
  13. Glauber H, Brown J. Impact of cardiovascular disease on health care utilization in a defined diabetic population. J Clin Epidemiol. 1994;47(10):1133–1142
  14. Rathmann W. Costs and effectiveness of medications in diabetes patients. Drug Benefit Trends. 1998;10(3):24–2732–33
  15. Harris MI. Impaired glucose tolerance in the U.S. population. Diabetes Care. 1989;12(7):464–474
  16. Stern MP. Diabetes and cardiovascular disease. The “common soil” hypothesis. Diabetes. 1995;44(4):369–374
  17. Mykkanen L, Kuusisto J, Pyorala K, Laakso M. Cardiovascular disease risk factors as predictors of type 2 (non- insulin-dependent) diabetes mellitus in elderly subjects. Diabetologia. 1993;36(6):553–559
  18. Salomaa VV, Strandberg TE, Vanhanen H, Naukkarinen V, Sarna S, Miettinen TA. Glucose tolerance and blood pressure (long term follow up in middle aged men). BMJ. 1991;302(6775):493–496
  19. Fagot-Campagna A, Charles MA, Thibult N, Richard JL, Claude JR, Warnet JM, et al. Is insulin an independent risk factor for hypertension? The Paris Prospective Study. Int J Epidemiol. 1997;26(3):542–550
  20. Fontbonne A, Charles MA, Thibult N, Richard JL, Claude JR, Warnet JM, et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population (the Paris Prospective Study, 15-year follow-up). Diabetologia. 1991;34(5):356–361
  21. Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21(3):360–367
  22. Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM. Development of a type 2 diabetes symptom checklist (a measure of symptom severity). Diabet Med. 1994;11(3):253–261
  23. Rutten G, Verhoeven S, Heine RJ, De Grauw WJC, Cromme PVM, Reenders K, van Ballegooie E, Wiersma TJ. [NHG-Standard Diabetes Mellitus Type 2 (first revision)]. Huisarts Wet 1999;42(2):67–84.
  24. Standl E, Stiegler H. Microalbuminuria in a random cohort of recently diagnosed type 2 (non- insulin-dependent) diabetic patients living in the greater Munich area. Diabetologia. 1993;36(10):1017–1020
  25. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care. 1992;15(7):815–819
  26. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) . UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853
  27. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 . UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703–713
  28. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20(4):614–620
  29. Groop L, Forsblom C, Lehtovirta M. Characterization of the prediabetic state. Am J Hypertens. 1997;10(9 Pt 2):172S–180S

☆ This study was supported by an unrestricted NovoNordisk Fellowship.

PII: S0895-4356(01)00482-6

Journal of Clinical Epidemiology
Volume 55, Issue 4 , Pages 345-349 , April 2002

Article Tools

* Image Usage & Resolution